Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neo-VIKTORY: Perioperative Therapies in Locally Advanced Unresectable Gastric Cancer
NCT06630130Phase 2Recruiting
- Start
- Jan 2025
- Primary completion
- Oct 2028
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of trastuzumab deruxtecan, rilvegostomig, sonesitatug vedotin, durvalumab in gastric cancer (GC), gastroesophageal junction cancer. Started Jan 2025; status: recruiting.
02
Drugs
trastuzumab deruxtecanrilvegostomigsonesitatug vedotindurvalumab
03
Conditions
gastric cancer (GC)gastroesophageal junction cancer
Beyond the preview
Go deeper on NCT06630130.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06630130.